Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.16 | 5e-06 |
mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0001 |
mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0004 |
mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0004 |
mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0005 |
mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.4 | 0.0006 |
mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.38 | 0.0007 |
mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.002 |
mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.15 | 0.002 |